The U.S. Food and Drug Administration (FDA) has granted approval for Abbreviated New Drug Application (ANDA) 207417 covering methylphenidate hydrochloride oral solution.
The approved products are manufactured by Ascent Pharmaceuticals, Inc. (listed as sponsor Ascent Pharm Inc) and are available in two strengths: 5 mg/5 mL and 10 mg/5 mL. Both are oral solutions indicated for prescription use.
The products carry National Drug Code (NDC) identifiers 43602-177-25, 43602-177-05, 43602-178-25, and 43602-178-05 and are classified as human prescription drugs with central nervous system stimulant activity.
The FDA submission record shows an original submission (type ORIG) approved on 2021‑01‑29 and a labeling supplement approved on 2025‑06‑06.
Cập nhật pháp chế2 thg 9, 2026•1 phút đọc
FDA Approves Methylphenidate Hydrochloride Oral Solution (ANDA 207417)
FDA has approved ANDA 207417 for methylphenidate hydrochloride oral solution, 5 mg/5 mL and 10 mg/5 mL strengths, manufactured by Ascent Pharmaceuticals.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá